[pubmed] Determinants of Quality of Life in Myasthenia Gravis Patients

[RSS-Bot]

Front Neurol. 2020 Sep 23;11:553626. doi: 10.3389/fneur.2020.553626. eCollection 2020.

ABSTRACT

Background: Although approximately half of myasthenia gravis (MG) patents achieve remission, for the remaining group MG is often a life-long disease. Better understanding of the determinants of Quality of Life (QoL) in MG is needed to optimize treatment goals in chronic cases. Materials and Methods: We performed a single center cross-sectional study in 339 MG adult patients (64.9% women), with ocular or generalized disease. SF-36 and a structured questionnaire was administered, including information on previous and current MG severity, medications, comorbidities, education, occupation and BMI of the patient. Mean disease duration was 7.5 + 9.3 years. Current age was 51.6 + 18.3 years, 55% had Early-Onset (

Source: https://pubmed.ncbi.nlm.nih.gov/3307194 ... 8&v=2.12.5